{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T10:13:47Z","timestamp":1792059227411,"version":"4.4.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T00:00:00Z","timestamp":1481587200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1038\/nrurol.2016.254","type":"journal-article","created":{"date-parts":[[2016,12,13]],"date-time":"2016-12-13T11:05:47Z","timestamp":1481627147000},"page":"79-89","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy"],"prefix":"10.1038","volume":"14","author":[{"given":"Teruyuki","family":"Ogawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuji","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadako","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Ishizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeya","family":"Kitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,12,13]]},"reference":[{"key":"BFnrurol2016254_CR1","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1093\/brain\/99.2.269","volume":"99","author":"KA Flowers","year":"1976","unstructured":"Flowers, K. A. Visual \u201cclosed-loop\u201d and \u201copen-loop\u201d characteristics of voluntary movement in patients with Parkinsonism and intention tremor. Brain 99, 269\u2013310 (1976).","journal-title":"Brain"},{"key":"BFnrurol2016254_CR2","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/brain\/104.1.167","volume":"104","author":"EV Evarts","year":"1981","unstructured":"Evarts, E. V., Teravainen, H. & Calne, D. B. Reaction time in Parkinson's disease. Brain 104, 167\u2013186 (1981).","journal-title":"Brain"},{"key":"BFnrurol2016254_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.nbd.2011.10.002","volume":"46","author":"R Sakakibara","year":"2012","unstructured":"Sakakibara, R. et al. Pathophysiology of bladder dysfunction in Parkinson's disease. Neurobiol. Dis. 46, 565\u2013571 (2012).","journal-title":"Neurobiol. Dis."},{"key":"BFnrurol2016254_CR4","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/jnnp.68.1.65","volume":"68","author":"R Sakakibara","year":"2000","unstructured":"Sakakibara, R. et al. Urinary dysfunction and orthostatic hypotension in multiple system atrophy: which is the more common and earlier manifestation? Journal of Neurology, Neurosurgery, and Psychiatry 68, 65\u201369 (2000).","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"BFnrurol2016254_CR5","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1002\/mds.22332","volume":"24","author":"T Yamamoto","year":"2009","unstructured":"Yamamoto, T. et al. Questionnaire-based assessment of pelvic organ dysfunction in multiple system atrophy. Mov. Disord. 24, 972\u2013978 (2009).","journal-title":"Mov. Disord."},{"key":"BFnrurol2016254_CR6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/j.2040-4603.2015.tb00596.x","volume":"5","author":"WC de Groat","year":"2015","unstructured":"de Groat, W. C., Griffiths, D. & Yoshimura, N. Neural control of the lower urinary tract. Compr. Physiol. 5, 327\u2013396 (2015).","journal-title":"Compr. Physiol."},{"key":"BFnrurol2016254_CR7","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1016\/S0140-6736(09)60492-X","volume":"373","author":"AJ Lees","year":"2009","unstructured":"Lees, A. J., Hardy, J. & Revesz, T. Parkinson's disease. Lancet 373, 2055\u20132066 (2009).","journal-title":"Lancet"},{"key":"BFnrurol2016254_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0022-510X(01)00521-4","volume":"187","author":"R Sakakibara","year":"2001","unstructured":"Sakakibara, R. et al. SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction. J. Neurol. Sci. 187, 55\u201359 (2001).","journal-title":"J. Neurol. Sci."},{"key":"BFnrurol2016254_CR9","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/mds.20867","volume":"21","author":"K Winge","year":"2006","unstructured":"Winge, K. & Fowler, C. J. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov. Disord. 21, 737\u2013745 (2006).","journal-title":"Mov. Disord."},{"key":"BFnrurol2016254_CR10","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/S0022-5347(05)00324-1","volume":"175","author":"T Kitta","year":"2006","unstructured":"Kitta, T. et al. Brain activation during detrusor overactivity in patients with Parkinson's disease: a positron emission tomography study. J. Urol. 175, 994\u2013998 (2006).","journal-title":"J. Urol."},{"key":"BFnrurol2016254_CR11","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1002\/nau.1930110509","volume":"11","author":"N Yoshimura","year":"1992","unstructured":"Yoshimura, N., Sasa, M., yoshida, O. & Takaori, S. Dopamine D1 receptor-mediated inhibition of micturition reflex by central dopamine from the substantia nigra. Neurourol. Urodynam. 11, 535\u2013545 (1992).","journal-title":"Neurourol. Urodynam."},{"key":"BFnrurol2016254_CR12","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.neuroscience.2005.06.007","volume":"135","author":"T Yamamoto","year":"2005","unstructured":"Yamamoto, T. et al. Striatal dopamine level increases in the urinary storage phase in cats: an in vivo microdialysis study. Neuroscience 135, 299\u2013303 (2005).","journal-title":"Neuroscience"},{"key":"BFnrurol2016254_CR13","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/0304-3940(88)90143-7","volume":"87","author":"A Albanease","year":"1988","unstructured":"Albanease, A., Jenner, P., Marsden, C. D. & Stephenson, J. D. Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurosci. Lett. 87, 46\u201350 (1988).","journal-title":"Neurosci. Lett."},{"key":"BFnrurol2016254_CR14","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0028-3908(93)90151-R","volume":"32","author":"N Yoshimura","year":"1993","unstructured":"Yoshimura, N., Mizuta, E., Kuno, S., Sasa, M. & Yoshida, O. The dopamine D1 receptor agonist SKF 38393 suppresses detrusor hyperreflexia in the monkey with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuropharmacology 32, 315\u2013321 (1993).","journal-title":"Neuropharmacology"},{"key":"BFnrurol2016254_CR15","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0022-3565(24)37579-2","volume":"286","author":"N Yoshimura","year":"1998","unstructured":"Yoshimura, N., Mizuta, E., Yoshida, O. & Kuno, S. Therapeutic effects of dopamine D1\/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. J. Pharmacol. Exp. Ther. 286, 228\u2013233 (1998).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrurol2016254_CR16","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1038\/sj.bjp.0705388","volume":"139","author":"N Yoshimura","year":"2003","unstructured":"Yoshimura, N., Kuno, S., Chancellor, M. B., de Groat, W. C. & Seki, S. Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway. Br. J. Pharmacol. 139, 1425\u20131432 (2003).","journal-title":"Br. J. Pharmacol."},{"key":"BFnrurol2016254_CR17","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1002\/acn3.246","volume":"2","author":"C Buddhala","year":"2015","unstructured":"Buddhala, C. et al. Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. Ann. Clin. Transl. Neurol. 2, 949\u2013959 (2015).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"BFnrurol2016254_CR18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1136\/jnnp.32.1.28","volume":"32","author":"JG Graham","year":"1969","unstructured":"Graham, J. G. & Oppenheimer, D. R. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 32, 28\u201334 (1969).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrurol2016254_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/0022-510X(89)90219-0","volume":"94","author":"MI Papp","year":"1989","unstructured":"Papp, M. I., Kahn, J. E. & Lantos, P. L. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J. Neurol. Sci. 94, 79\u2013100 (1989).","journal-title":"J. Neurol. Sci."},{"key":"BFnrurol2016254_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1365-2990.2011.01234.x","volume":"38","author":"Z Ahmed","year":"2012","unstructured":"Ahmed, Z. et al. The neuropathology, pathophysiology and genetics of multiple system atrophy. Neuropathol. Appl. Neurobiol. 38, 4\u201324 (2012).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"BFnrurol2016254_CR21","first-page":"2046","volume":"74","author":"SS Rao","year":"2006","unstructured":"Rao, S. S., Hofmann, L. A. & Shakil, A. Parkinson's disease: diagnosis and treatment. Am. Fam. Physician 74, 2046\u20132054 (2006).","journal-title":"Am. Fam. Physician"},{"key":"BFnrurol2016254_CR22","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/mds.25336","volume":"28","author":"M Boudes","year":"2013","unstructured":"Boudes, M. et al. Bladder dysfunction in a transgenic mouse model of multiple system atrophy. Mov. Disord. 28, 347\u2013355 (2013).","journal-title":"Mov. Disord."},{"key":"BFnrurol2016254_CR23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1136\/jnnp.68.4.429","volume":"68","author":"I Araki","year":"2000","unstructured":"Araki, I. & Kuno, S. Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score. J. Neurol. Neurosurg. Psychiatry 68, 429\u2013433 (2000).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrurol2016254_CR24","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/S0090-4295(00)00641-5","volume":"56","author":"GE Lemack","year":"2000","unstructured":"Lemack, G. E. et al. Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson's disease. Urology 56, 250\u2013254 (2000).","journal-title":"Urology"},{"key":"BFnrurol2016254_CR25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1590\/S0004-282X2003000300007","volume":"61","author":"RN Campos-Sousa","year":"2003","unstructured":"Campos-Sousa, R. N. et al. Urinary symptoms in Parkinson's disease: prevalence and associated factors. Arq. Neuropsiquiatr. 61, 359\u2013363 (2003).","journal-title":"Arq. Neuropsiquiatr."},{"key":"BFnrurol2016254_CR26","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/S0022-5347(17)51929-1","volume":"129","author":"AJ Pavlakis","year":"1983","unstructured":"Pavlakis, A. J., Siroky, M. B., Goldstein, I. & Krane, R. J. Neurologic findings in Parkinson's disease. J. Urol. 129, 80\u201383 (1983).","journal-title":"J. Urol."},{"key":"BFnrurol2016254_CR27","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/j.1464-410X.1985.tb07025.x","volume":"57","author":"H Fitzmaurice","year":"1985","unstructured":"Fitzmaurice, H. et al. Micturition disturbance in Parkinson's disease. Br. J. Urol. 57, 652\u2013656 (1985).","journal-title":"Br. J. Urol."},{"key":"BFnrurol2016254_CR28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1046\/j.1464-410X.1997.00249.x","volume":"80","author":"VA Chandiramani","year":"1997","unstructured":"Chandiramani, V. A., Palace, J. & Fowler, C. J. How to recognize patients with parkinsonism who should not have urological surgery. Br. J. Urol. 80, 100\u2013104 (1997).","journal-title":"Br. J. Urol."},{"key":"BFnrurol2016254_CR29","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1002\/mds.870120406","volume":"12","author":"AM Bonnet","year":"1997","unstructured":"Bonnet, A. M. et al. Urinary disturbances in striatonigral degeneration and Parkinson's disease: clinical and urodynamic aspects. Mov. Disord. 12, 509\u2013513 (1997).","journal-title":"Mov. Disord."},{"key":"BFnrurol2016254_CR30","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/S0090-4295(03)00507-7","volume":"62","author":"GA Defreitas","year":"2003","unstructured":"Defreitas, G. A. et al. Distinguishing neurogenic from non-neurogenic detrusor overactivity: a urodynamic assessment of lower urinary tract symptoms in patients with and without Parkinson's disease. Urology 62, 651\u2013655 (2003).","journal-title":"Urology"},{"key":"BFnrurol2016254_CR31","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.purol.2015.02.004","volume":"25","author":"J Romain","year":"2015","unstructured":"Romain, J., Torny, F., Dumas, J. P., Game, X. & Descazeaud, A. Is nocturnal polyuria more frequent among patients with Parkinson's disease? Prog. Urol. 25, 312\u2013317 (2015).","journal-title":"Prog. Urol."},{"key":"BFnrurol2016254_CR32","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/nau.20193","volume":"25","author":"K Winge","year":"2006","unstructured":"Winge, K., Skau, A. M., Stimpel, H., Nielsen, K. K. & Werdelin, L. Prevalence of bladder dysfunction in Parkinsons disease. Neurourol.Urodyn. 25, 116\u2013122 (2006).","journal-title":"Neurourol.Urodyn."},{"key":"BFnrurol2016254_CR33","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1016\/S0140-6736(88)90932-4","volume":"2","author":"TJ Christmas","year":"1988","unstructured":"Christmas, T. J. et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 2, 1451\u20131453 (1988).","journal-title":"Lancet"},{"key":"BFnrurol2016254_CR34","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/jnnp.71.5.600","volume":"71","author":"R Sakakibara","year":"2001","unstructured":"Sakakibara, R., Hattori, T., Uchiyama, T. & Yamanishi, T. Videourodynamic and sphincter motor unit potential analyses in Parkinson's disease and multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 71, 600\u2013606 (2001).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrurol2016254_CR35","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/0090-4295(89)90139-8","volume":"33","author":"Z Khan","year":"1989","unstructured":"Khan, Z., Starer, P. & Bhola, A. Urinary incontinence in female Parkinson disease patients. Pitfalls of diagnosis. Urology 33, 486\u2013489 (1989).","journal-title":"Urology"},{"key":"BFnrurol2016254_CR36","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/ageing\/24.6.499","volume":"24","author":"R Gray","year":"1995","unstructured":"Gray, R., Stern, G. & Malone-Lee, J. Lower urinary tract dysfunction in Parkinson's disease: changes relate to age and not disease. Age Ageing 24, 499\u2013504 (1995).","journal-title":"Age Ageing"},{"key":"BFnrurol2016254_CR37","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1136\/jnnp.62.5.507","volume":"62","author":"F Stocchi","year":"1997","unstructured":"Stocchi, F. et al. Urodynamic and neurophysiological evaluation in Parkinson's disease and multiple system atrophy. J. Neurol. Neurosurg. Psychiatry 62, 507\u2013511 (1997).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrurol2016254_CR38","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s001920050043","volume":"10","author":"DL Myers","year":"1999","unstructured":"Myers, D. L., Arya, L. A. & Friedman, J. H. Is urinary incontinence different in women with Parkinson's disease? Int. Urogynecol J. Pelvic Floor Dysfunct 10, 188\u2013191 (1999).","journal-title":"Int. Urogynecol J. Pelvic Floor Dysfunct"},{"key":"BFnrurol2016254_CR39","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/nau.20260","volume":"25","author":"T Ogawa","year":"2006","unstructured":"Ogawa, T. et al. Dopaminergic mechanisms controlling urethral function in rats. Neurourol. Urodyn. 25, 480\u2013489 (2006).","journal-title":"Neurourol. Urodyn."},{"key":"BFnrurol2016254_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2009.08.034","volume":"289","author":"D Aarsland","year":"2010","unstructured":"Aarsland, D. & Kurz, M. W. The epidemiology of dementia associated with Parkinson disease. J. Neurol. Sci. 289, 18\u201322 (2010).","journal-title":"J. Neurol. Sci."},{"key":"BFnrurol2016254_CR41","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1002\/mds.20527","volume":"20","author":"D Aarsland","year":"2005","unstructured":"Aarsland, D., Zaccai, J. & Brayne, C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov. Disord. 20, 1255\u20131263 (2005).","journal-title":"Mov. Disord."},{"key":"BFnrurol2016254_CR42","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1136\/jnnp.2004.046243","volume":"76","author":"R Sakakibara","year":"2005","unstructured":"Sakakibara, R. et al. Lower urinary tract function in dementia of Lewy body type. Journal of Neurology, Neurosurgery, and Psychiatry 76, 729\u2013732 (2005).","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"BFnrurol2016254_CR43","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/mds.25985","volume":"30","author":"F Tateno","year":"2015","unstructured":"Tateno, F. et al. Lower urinary tract function in dementia with Lewy bodies (DLB). Movement disorders: official journal of the Movement Disorder Society 30, 411\u2013415 (2015).","journal-title":"Movement disorders: official journal of the Movement Disorder Society"},{"key":"BFnrurol2016254_CR44","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1212\/01.wnl.0000296826.61499.26","volume":"70","author":"GN Ransmayr","year":"2008","unstructured":"Ransmayr, G. N. et al. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology 70, 299\u2013303 (2008).","journal-title":"Neurology"},{"key":"BFnrurol2016254_CR45","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1212\/WNL.49.5.1284","volume":"49","author":"JH Bower","year":"1997","unstructured":"Bower, J. H., Maraganore, D. M., McDonnell, S. K. & Rocca, W. A. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 49, 1284\u20131288 (1997).","journal-title":"Neurology"},{"key":"BFnrurol2016254_CR46","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10286-003-0034-5","volume":"13","author":"R Sakakibara","year":"2003","unstructured":"Sakakibara, R. et al. Amezinium metilsulfate, a sympathomimetic agent, may increase the risk of urinary retention in multiple system atrophy. Clin. Auton. Res. 13, 51\u201353 (2003).","journal-title":"Clin. Auton. Res."},{"key":"BFnrurol2016254_CR47","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nrneurol.2011.5","volume":"7","author":"C Colosimo","year":"2011","unstructured":"Colosimo, C. Nonmotor presentations of multiple system atrophy. Nat. Rev. Neurol. 7, 295\u2013298 (2011).","journal-title":"Nat. Rev. Neurol."},{"key":"BFnrurol2016254_CR48","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1212\/01.wnl.0000324625.00404.15","volume":"71","author":"S Gilman","year":"2008","unstructured":"Gilman, S. et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71, 670\u2013676 (2008).","journal-title":"Neurology"},{"key":"BFnrurol2016254_CR49","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/brain\/117.4.835","volume":"117","author":"GK Wenning","year":"1994","unstructured":"Wenning, G. K., Ben Shlomo, Y., Magalhaes, M., Daniel, S. E. & Quinn, N. P. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain 117, 835\u2013845 (1994).","journal-title":"Brain"},{"key":"BFnrurol2016254_CR50","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1007\/s00702-005-0381-6","volume":"112","author":"S Gilman","year":"2005","unstructured":"Gilman, S. et al. The North American Multiple System Atrophy Study Group. J. Neural Transm. 112, 1687\u20131694 (2005).","journal-title":"J. Neural Transm."},{"key":"BFnrurol2016254_CR51","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/nau.10052","volume":"21","author":"P Abrams","year":"2002","unstructured":"Abrams, P. et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol. Urodyn. 21, 167\u2013178 (2002).","journal-title":"Neurourol. Urodyn."},{"key":"BFnrurol2016254_CR52","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/sj.ijir.3901014","volume":"15","author":"K Kirchhof","year":"2003","unstructured":"Kirchhof, K., Apostolidis, A. N., Mathias, C. J. & Fowler, C. J. Erectile and urinary dysfunction may be the presenting features in patients with multiple system atrophy: a retrospective study. Int. J. Impot Res. 15, 293\u2013298 (2003).","journal-title":"Int. J. Impot Res."},{"key":"BFnrurol2016254_CR53","first-page":"551","volume":"5","author":"R Sakakibara","year":"2015","unstructured":"Sakakibara, R., Panicker, J., Finazzi-Agro, E., Iacovelli, V. & Bruschini, H. A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders. Neurourol. Urodyn. 5, 551\u2013563 (2015).","journal-title":"Neurourol. Urodyn."},{"key":"BFnrurol2016254_CR54","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.eururo.2015.07.071","volume":"69","author":"J Groen","year":"2016","unstructured":"Groen, J. et al. Summary of European Association of Urology (EAU) Guidelines on Neuro-Urology. Eur. Urol. 69, 324\u2013333 (2016).","journal-title":"Eur. Urol."},{"key":"BFnrurol2016254_CR55","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/0090-4295(76)90556-2","volume":"7","author":"GS Benson","year":"1976","unstructured":"Benson, G. S., Raezer, D. M., Anderson, J. R., Saunders, C. D. & Corriere, J. N. Jr. Effect of levodopa on urinary bladder. Urology 7, 24\u201328 (1976).","journal-title":"Urology"},{"key":"BFnrurol2016254_CR56","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1002\/nau.1930120302","volume":"12","author":"B Aranda","year":"1993","unstructured":"Aranda, B. & Cramer, P. Effects of apomorphine and L-dopa on the parkinsonian bladder. Neurourol. Urodyn. 12, 203\u2013209 (1993).","journal-title":"Neurourol. Urodyn."},{"key":"BFnrurol2016254_CR57","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1002\/mds.10403","volume":"18","author":"T Uchiyama","year":"2003","unstructured":"Uchiyama, T., Sakakibara, R., Hattori, T. & Yamanishi, T. Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon. Mov. Disord. 18, 573\u2013578 (2003).","journal-title":"Mov. Disord."},{"key":"BFnrurol2016254_CR58","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/S0022-5347(05)00058-3","volume":"175","author":"L Brusa","year":"2006","unstructured":"Brusa, L. et al. Central acute D2 stimulation worsens bladder function in patients with mild Parkinson's disease. J. Urol. 175, 202\u2013206 (2006).","journal-title":"J. Urol."},{"key":"BFnrurol2016254_CR59","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/iju.12421","volume":"21","author":"R Sakakibara","year":"2014","unstructured":"Sakakibara, R. et al. Bladder function of patients with Parkinson's disease. Int. J. Urol. 21, 638\u2013646 (2014).","journal-title":"Int. J. Urol."},{"key":"BFnrurol2016254_CR60","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/mds.22840","volume":"24","author":"T Uchiyama","year":"2009","unstructured":"Uchiyama, T. et al. Comparing bromocriptine effects with levodopa effects on bladder function in Parkinson's disease. Mov. Disord. 24, 2386\u20132390 (2009).","journal-title":"Mov. Disord."},{"key":"BFnrurol2016254_CR61","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.parkreldis.2003.08.001","volume":"10","author":"S Kuno","year":"2004","unstructured":"Kuno, S., Mizuta, E., Yamasaki, S. & Araki, I. Effects of pergolide on nocturia in Parkinson's disease: three female cases selected from over 400 patients. Parkinsonism Relat. Disord. 10, 181\u2013187 (2004).","journal-title":"Parkinsonism Relat. Disord."},{"key":"BFnrurol2016254_CR62","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.parkreldis.2014.04.020","volume":"20","author":"L Brusa","year":"2014","unstructured":"Brusa, L. et al. Rasagiline effect on bladder disturbances in early mild Parkinson's disease patients. Parkinsonism Relat. Disord. 20, 931\u2013932 (2014).","journal-title":"Parkinsonism Relat. Disord."},{"key":"BFnrurol2016254_CR63","first-page":"CD003735","volume":"2","author":"R Katzenschlager","year":"2003","unstructured":"Katzenschlager, R., Sampaio, C., Costa, J. & Lees, A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev, 2, CD003735 (2003).","journal-title":"Cochrane Database Syst Rev,"},{"key":"BFnrurol2016254_CR64","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/01.WNF.0000228177.75711.0f","volume":"29","author":"G Palleschi","year":"2006","unstructured":"Palleschi, G. et al. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment. Clin. Neuropharmacol. 29, 220\u2013229 (2006).","journal-title":"Clin. Neuropharmacol."},{"key":"BFnrurol2016254_CR65","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.parkreldis.2015.02.025","volume":"21","author":"TA Zesiewics","year":"2015","unstructured":"Zesiewics, T. A. et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease: Parkinsonism Relat. Disord. 21, 514\u2013520 (2015)","journal-title":"Relat. Disord."},{"key":"BFnrurol2016254_CR66","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S1566-0702(01)00295-8","volume":"92","author":"R Sakakibara","year":"2001","unstructured":"Sakakibara, R. et al. Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton. Neurosci. 92, 76\u201385 (2001).","journal-title":"Auton. Neurosci."},{"key":"BFnrurol2016254_CR67","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1136\/jnnp.45.12.1161","volume":"45","author":"Y de Smet","year":"1982","unstructured":"de Smet, Y. et al. Confusion, dementia and anticholinergics in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 45, 1161\u20131164 (1982).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"BFnrurol2016254_CR68","doi-asserted-by":"publisher","first-page":"e16718","DOI":"10.1371\/journal.pone.0016718","volume":"6","author":"TM Kessler","year":"2011","unstructured":"Kessler, T. M. et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS ONE 6, e16718 (2011).","journal-title":"PLoS ONE"},{"key":"BFnrurol2016254_CR69","doi-asserted-by":"publisher","first-page":"e2130","DOI":"10.1136\/bmj.e2130","volume":"344","author":"D Robinson","year":"2012","unstructured":"Robinson, D. & Cardozo, L. Antimuscarinic drugs to treat overactive bladder. BMJ 344, e2130 (2012).","journal-title":"BMJ"},{"key":"BFnrurol2016254_CR70","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.parkreldis.2010.06.006","volume":"16","author":"H Kulaksizoglu","year":"2010","unstructured":"Kulaksizoglu, H. & Parman, Y. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons's disease. Parkinsonism Relat. Disord. 16, 531\u2013534 (2010).","journal-title":"Parkinsonism Relat. Disord."},{"key":"BFnrurol2016254_CR71","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.juro.2009.06.023","volume":"182","author":"A Giannantoni","year":"2009","unstructured":"Giannantoni, A. et al. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. J. Urol. 182, 1453\u20131457 (2009).","journal-title":"J. Urol."},{"key":"BFnrurol2016254_CR72","unstructured":"Department of Health & Human Services, U. S. U. S. Food & Drug administration http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm269509.htm (2011)."},{"key":"BFnrurol2016254_CR73","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/bmj.293.6543.353","volume":"293","author":"CJ Mathias","year":"1986","unstructured":"Mathias, C. J., Fosbraey, P., da Costa, D. F., Thornley, A. & Bannister, R. The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. Br. Med. J. 293, 353\u2013354 (1986).","journal-title":"Br. Med. J."},{"key":"BFnrurol2016254_CR74","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s10286-003-0052-3","volume":"13","author":"R Sakakibara","year":"2003","unstructured":"Sakakibara, R. et al. The effect of intranasal desmopressin on nocturnal waking in urination in multiple system atrophy patients with nocturnal polyuria. Clin. Auton. Res. 13, 106\u2013108 (2003).","journal-title":"Clin. Auton. Res."},{"key":"BFnrurol2016254_CR75","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/S0165-1838(99)00105-8","volume":"79","author":"R Sakakibara","year":"2000","unstructured":"Sakakibara, R. et al. Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J. Auton. Nerv. Syst. 79, 191\u2013195 (2000).","journal-title":"J. Auton. Nerv. Syst."},{"key":"BFnrurol2016254_CR76","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/mds.20815","volume":"21","author":"T Ito","year":"2006","unstructured":"Ito, T. et al. Incomplete emptying and urinary retention in multiple-system atrophy: when does it occur and how do we manage it? Mov. Disord. 21, 816\u2013823 (2006).","journal-title":"Mov. Disord."},{"key":"BFnrurol2016254_CR77","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1046\/j.1464-410X.2000.00098.x","volume":"86","author":"DA Schwinn","year":"2000","unstructured":"Schwinn, D. A. Novel role for alpha1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU international 86, 11\u201320 (2000).","journal-title":"BJU international"},{"key":"BFnrurol2016254_CR78","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1442-2042.2004.00753.x","volume":"11","author":"T Yamanishi","year":"2004","unstructured":"Yamanishi, T. et al. Combination of a cholinergic drug and an alpha-blocker is more effective than monotherapy for the treatment of voiding difficulty in patients with underactive detrusor. Int. J. Urol. 11, 88\u201396 (2004).","journal-title":"Int. J. Urol."},{"key":"BFnrurol2016254_CR79","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10286-005-0225-3","volume":"15","author":"P Sandroni","year":"2005","unstructured":"Sandroni, P., Opfer-Gehrking, T. L., Singer, W. & Low, P. A. Pyridostigmine for treatment of neurogenic orthostatic hypotension [correction of hypertension]\u2014a follow-up survey study. Clin. Auton. Res. 15, 51\u201353 (2005).","journal-title":"Clin. Auton. Res."},{"key":"BFnrurol2016254_CR80","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s10286-006-0358-z","volume":"16","author":"T Yamamoto","year":"2006","unstructured":"Yamamoto, T. et al. Pyridostigmine in autonomic failure: can we treat postural hypotension and bladder dysfunction with one drug? Clin. Auton. Res. 16, 296\u2013298 (2006).","journal-title":"Clin. Auton. Res."},{"key":"BFnrurol2016254_CR81","first-page":"877","volume":"49","author":"M Takahashi","year":"2011","unstructured":"Takahashi, M. et al. [Acute respiratory failure associated with cholinergic crisis: report of five cases and review of the literature]. Nihon Kokyuki Gakkai Zasshi. 49, 877\u2013884 (2011).","journal-title":"Nihon Kokyuki Gakkai Zasshi."},{"key":"BFnrurol2016254_CR82","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1002\/mds.10143","volume":"17","author":"JO Dostrovsky","year":"2002","unstructured":"Dostrovsky, J. O. & Lozano, A. M. Mechanisms of deep brain stimulation. Mov. Disord. 17, S63\u201368 (2002).","journal-title":"Mov. Disord."},{"key":"BFnrurol2016254_CR83","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1097\/01.ju.0000055520.88377.dc","volume":"169","author":"E Finazzi-Agro","year":"2003","unstructured":"Finazzi-Agro, E. et al. Effects of subthalamic nucleus stimulation on urodynamic findings in patients with Parkinson's disease. J. Urol. 169, 1388\u20131391 (2003).","journal-title":"J. Urol."},{"key":"BFnrurol2016254_CR84","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/ana.10806","volume":"55","author":"C Seif","year":"2004","unstructured":"Seif, C. et al. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann. Neurol. 55, 118\u2013120 (2004).","journal-title":"Ann. Neurol."},{"key":"BFnrurol2016254_CR85","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1093\/brain\/awl302","volume":"129","author":"J Herzog","year":"2006","unstructured":"Herzog, J. et al. Subthalamic stimulation modulates cortical control of urinary bladder in Parkinson's disease. Brain 129, 3366\u20133375 (2006).","journal-title":"Brain"},{"key":"BFnrurol2016254_CR86","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0306-4522(03)00319-1","volume":"120","author":"R Sakakibara","year":"2003","unstructured":"Sakakibara, R. et al. Effects of subthalamic nucleus stimulation on the micturation reflex in cats. Neuroscience 120, 871\u2013875 (2003).","journal-title":"Neuroscience"},{"key":"BFnrurol2016254_CR87","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/nau.20026","volume":"23","author":"AL Dalmose","year":"2004","unstructured":"Dalmose, A. L., Bjarkam, C. R., Sorensen, J. C., Djurhuus, J. C. & Jorgensen, T. M. Effects of high frequency deep brain stimulation on urine storage and voiding function in conscious minipigs. Neurourol. Urodyn. 23, 265\u2013272 (2004).","journal-title":"Neurourol. Urodyn."},{"key":"BFnrurol2016254_CR88","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/WON.0000000000000078","volume":"42","author":"MC Perissinotto","year":"2015","unstructured":"Perissinotto, M. C., D'Ancona, C. A., Lucio, A., Campos, R. M. & Abreu, A. Transcutaneous tibial nerve stimulation in the treatment of lower urinary tract symptoms and its impact on health-related quality of life in patients with Parkinson disease: a randomized controlled trial. J. Wound Ostomy Continence Nurs. 42, 94\u201399 (2015).","journal-title":"J. Wound Ostomy Continence Nurs."},{"key":"BFnrurol2016254_CR89","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.urology.2015.09.026","volume":"87","author":"S Kabay","year":"2016","unstructured":"Kabay, S. et al. The Clinical and Urodynamic Results of Percutaneous Posterior Tibial Nerve Stimulation on Neurogenic Detrusor Overactivity in Patients With Parkinson's Disease. Urology 87, 76\u201381 (2016).","journal-title":"Urology"},{"key":"BFnrurol2016254_CR90","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.eururo.2005.12.042","volume":"50","author":"J Rassweiler","year":"2006","unstructured":"Rassweiler, J. et al.Complications of transurethral resection of the prostate (TURP)\u2014incidence, management, and prevention. Eur Urol 50, 969\u2013979 (2006).","journal-title":"Eur Urol"},{"key":"BFnrurol2016254_CR91","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/S0022-5347(17)41501-1","volume":"140","author":"DS Staskin","year":"1988","unstructured":"Staskin, D. S., Vardi, Y. & Siroky, M. B. Post-prostatectomy continence in the parkinsonian patient: the significance of poor voluntary sphincter control. J. Urol. 140, 117\u2013118 (1988).","journal-title":"J. Urol."},{"key":"BFnrurol2016254_CR92","first-page":"277","volume":"16","author":"CJ Fowler","year":"2001","unstructured":"Fowler, C. J. Urinary disorders in Parkinson's disease and multiple system atrophy. Funct. Neurol. 16, 277\u2013282 (2001).","journal-title":"Funct. Neurol."},{"key":"BFnrurol2016254_CR93","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1136\/bmj.310.6977.447","volume":"310","author":"N Quinn","year":"1995","unstructured":"Quinn, N. Parkinsonism\u2014recognition and differential diagnosis. BMJ 310, 447\u2013452 (1995).","journal-title":"BMJ"},{"key":"BFnrurol2016254_CR94","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1016\/j.juro.2009.01.049","volume":"181","author":"B Roth","year":"2009","unstructured":"Roth, B., Studer, U. E., Fowler, C. J. & Kessler, T. M. Benign prostatic obstruction and parkinson's disease\u2014should transurethral resection of the prostate be avoided? J. Urol. 181, 2209\u20132213 (2009).","journal-title":"J. Urol."},{"key":"BFnrurol2016254_CR95","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1016\/j.lfs.2005.04.029","volume":"77","author":"A Pinna","year":"2005","unstructured":"Pinna, A., Wardas, J., Simola, N. & Morelli, M. New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. Life Sci. 77, 3259\u20133267 (2005).","journal-title":"Life Sci."},{"key":"BFnrurol2016254_CR96","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.tins.2006.09.004","volume":"29","author":"MA Schwarzschild","year":"2006","unstructured":"Schwarzschild, M. A., Agnati, L., Fuxe, K., Chen, J. F. & Morelli, M. Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci. 29, 647\u2013654 (2006).","journal-title":"Trends Neurosci."},{"key":"BFnrurol2016254_CR97","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/mds.25418","volume":"28","author":"Y Mizuno","year":"2013","unstructured":"Mizuno, Y. et al. Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease. Mov. Disord. 28, 1138\u20131141 (2013).","journal-title":"Mov. Disord."},{"key":"BFnrurol2016254_CR98","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1016\/j.juro.2011.12.062","volume":"187","author":"T Kitta","year":"2012","unstructured":"Kitta, T. et al. Suppression of bladder overactivity by adenosine A2A receptor antagonist in a rat model of Parkinson disease. J. Urol. 187, 1890\u20131897 (2012).","journal-title":"J. Urol."},{"issue":"10","key":"BFnrurol2016254_CR99","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1111\/iju.13160","volume":"23","author":"Takeya Kitta","year":"2016","unstructured":"Kitta, T. et al. Clinical efficacy of istradefylline on lower urinary tract symptoms in Parkinson's disease. Int. J. Urol. 23, 893\u2013894.","journal-title":"International Journal of Urology"},{"key":"BFnrurol2016254_CR100","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1179\/1743132814Y.0000000375","volume":"36","author":"C Zhu","year":"2014","unstructured":"Zhu, C. et al. Adenosine A2A receptor antagonist istradefylline 20 versus 40 mg\/day as augmentation for Parkinson's disease: a meta-analysis. Neurol. Res. 36, 1028\u20131034 (2014).","journal-title":"Neurol. Res."},{"key":"BFnrurol2016254_CR101","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ydbio.2013.04.014","volume":"379","author":"SV Hegarty","year":"2013","unstructured":"Hegarty, S. V., Sullivan, A. M. & O'Keeffe, G. W. Midbrain dopaminergic neurons: a review of the molecular circuitry that regulates their development. Dev. Biol. 379, 123\u2013138 (2013).","journal-title":"Dev. Biol."},{"key":"BFnrurol2016254_CR102","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/mds.25378","volume":"28","author":"O Lindvall","year":"2013","unstructured":"Lindvall, O. Developing dopaminergic cell therapy for Parkinson's disease\u2014give up or move forward? Mov. Disord. 28, 268\u2013273 (2013).","journal-title":"Mov. Disord."},{"key":"BFnrurol2016254_CR103","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1248\/bpb.b12-00929","volume":"36","author":"K Nishimura","year":"2013","unstructured":"Nishimura, K. & Takahashi, J. Therapeutic application of stem cell technology toward the treatment of Parkinson's disease. Biol. Pharm. Bull. 36, 171\u2013175 (2013).","journal-title":"Biol. Pharm. Bull."},{"key":"BFnrurol2016254_CR104","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.juro.2011.11.079","volume":"187","author":"R Soler","year":"2012","unstructured":"Soler, R. et al. Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease. J. Urol. 187, 1491\u20131497 (2012).","journal-title":"J. Urol."},{"key":"BFnrurol2016254_CR105","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/S1474-4422(12)70327-7","volume":"12","author":"GK Wenning","year":"2013","unstructured":"Wenning, G. K. et al. The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol. 12, 264\u2013274 (2013).","journal-title":"Lancet Neurol."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2016.254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2016.254","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrurol.2016.254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T14:53:22Z","timestamp":1749826402000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrurol.2016.254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,13]]},"references-count":105,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["BFnrurol2016254"],"URL":"https:\/\/doi.org\/10.1038\/nrurol.2016.254","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,13]]},"assertion":[{"value":"13 December 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.Y. has received research funding from Astellas, GSK and Ono. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}